Centes­sa's pub­lic of­fer­ing; Vivory­on ends Ph2 Alzheimer’s tri­al

Plus, news about EXO Bi­o­log­ics:

Centes­sa prices pub­lic of­fer­ing: The start­up aims to raise $93.5 mil­lion, or up to $107.6 mil­lion if all op­tions are ex­er­cised. The fund­ing would ex­tend its run­way in­to mid-2026. On Mon­day, Centes­sa an­nounced the FDA cleared the IND for its nar­colep­sy pro­gram, called ORX750. A Phase 1 healthy vol­un­teer study is set to start dos­ing “im­mi­nent­ly,” with da­ta ex­pect­ed in the sec­ond half of this year. — Max Gel­man

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER